bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Authors: Baird Richard D. , van Rossum Annelot G.J. , Oliveira Mafalda , Beelen Karin , Gao Meiling , Schrier Mariette , Mandjes Ingrid A.M. , Garcia-Corbacho Javier , Vallier Anne-Laure , Dougall Greig , van Werkhoven Erik , Linossi Constanza , Kumar Sanjeev , van Tinteren Harm , Callari Maurizio , Beddowes Emma , Perez-Garcia José-Manuel , Rosing Hilde , Platte Else , Nederlof Petra , Schot Margaret , de Vries Schultink Aurelia , Bernards René , Saura Cristina , Gallagher William , Cortès Javier , Caldas Carlos , Linn Sabine C.
Published: April 2023

Supplementary Methods Text
Figure S4 from Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations
Authors: Rodrigues Manuel , Mobuchon Lenha , Houy Alexandre , Alsafadi Samar , Baulande Sylvain , Mariani Odette , Marande Benjamin , Ait Rais Khadija , Van der Kooij Monique K. , Kapiteijn Ellen , Gassama Sieta , Gardrat Sophie , Barnhill Raymond L. , Servois Vincent , Dendale Rémi , Putterman Marc , Tick Sarah , Piperno-Neumann Sophie , Cassoux Nathalie , Pierron Gaëlle , Waterfall Joshua J. , Roman-Roman Sergio , Mariani Pascale , Stern Marc-Henri
Published: April 2023

Supplementary figure 4 - Phylogenetic trees based on SNVs - MBD4pro cases with primary samples
Supplementary Tables S5-S7 from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Authors: Cidado Justin , Boiko Scott , Proia Theresa , Ferguson Douglas , Criscione Steven W. , San Martin Maryann , Pop-Damkov Petar , Su Nancy , Roamio Franklin Valar Nila , Sekhar Reddy Chilamakuri Chandra , D'Santos Clive S. , Shao Wenlin , Saeh Jamal C. , Koch Raphael , Weinstock David M. , Zinda Michael , Fawell Stephen E. , Drew Lisa
Published: April 2023

List of proteins modulated by AZD4573 (S5), genes rapidly modulated by AZD4573 (S6), and AZD4573 cancer cell line pharmacology (S7).
Supplementary Table S3 from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Authors: Nowicki Theodore S. , Berent-Maoz Beata , Cheung-Lau Gardenia , Huang Rong Rong , Wang Xiaoyan , Tsoi Jennifer , Kaplan-Lefko Paula , Cabrera Paula , Tran Justin , Pang Jia , Macabali Mignonette , Garcilazo Ivan Perez , Carretero Ignacio Baselga , Kalbasi Anusha , Cochran Alistair J. , Grasso Catherine S. , Hu-Lieskovan Siwen , Chmielowski Bartosz , Comin-Anduix Begoña , Singh Arun , Ribas Antoni
Published: April 2023

Summary of manufacturing and administration results.
Supplementary Table S2 from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Authors: Nowicki Theodore S. , Berent-Maoz Beata , Cheung-Lau Gardenia , Huang Rong Rong , Wang Xiaoyan , Tsoi Jennifer , Kaplan-Lefko Paula , Cabrera Paula , Tran Justin , Pang Jia , Macabali Mignonette , Garcilazo Ivan Perez , Carretero Ignacio Baselga , Kalbasi Anusha , Cochran Alistair J. , Grasso Catherine S. , Hu-Lieskovan Siwen , Chmielowski Bartosz , Comin-Anduix Begoña , Singh Arun , Ribas Antoni
Published: April 2023

Summary of Grade 3 or higher adverse events experienced by trial patients.
Supplementary Methods from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Authors: Nowicki Theodore S. , Berent-Maoz Beata , Cheung-Lau Gardenia , Huang Rong Rong , Wang Xiaoyan , Tsoi Jennifer , Kaplan-Lefko Paula , Cabrera Paula , Tran Justin , Pang Jia , Macabali Mignonette , Garcilazo Ivan Perez , Carretero Ignacio Baselga , Kalbasi Anusha , Cochran Alistair J. , Grasso Catherine S. , Hu-Lieskovan Siwen , Chmielowski Bartosz , Comin-Anduix Begoña , Singh Arun , Ribas Antoni
Published: April 2023

Supplementary Methods
Supplementary Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
Authors: Colclough Nicola , Chen Kan , Johnström Peter , Strittmatter Nicole , Yan Yumei , Wrigley Gail L. , Schou Magnus , Goodwin Richard , Varnäs Katarina , Adua Sally J. , Zhao Minghui , Nguyen Don X. , Maglennon Gareth , Barton Peter , Atkinson James , Zhang Lin , Janefeldt Annika , Wilson Joanne , Smith Aaron , Takano Akihiro , Arakawa Ryosuke , Kondrashov Mikhail , Malmquist Jonas , Revunov Evgeny , Vazquez-Romero Ana , Moein Mohammad Mahdi , Windhorst Albert D. , Karp Natasha A. , Finlay M. Raymond V. , Ward Richard A. , Yates James W.T. , Smith Paul D. , Farde Lars , Cheng Zack , Cross Darren A.E.
Published: April 2023

Supplementary Data
Suppl Fig 3 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

Maintenance of RG7388 resistance after withdrawal of permanent RG7388 exposure.
Supplementary Figure 3 from Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Authors: Pearson Alex , Proszek Paula , Pascual Javier , Fribbens Charlotte , Shamsher Monee K. , Kingston Belinda , O'Leary Ben , Herrera-Abreu Maria T. , Cutts Rosalind J. , Garcia-Murillas Isaac , Bye Hannah , Walker Brian A. , Gonzalez De Castro David , Yuan Lina , Jamal Sabri , Hubank Mike , Lopez-Knowles Elena , Schuster Eugene F. , Dowsett Mitch , Osin Peter , Nerurkar Ashutosh , Parton Marina , Okines Alicia F.C. , Johnston Stephen R.D. , Ring Alistair , Turner Nicholas C.
Published: April 2023

NCOR expression in NF1 mutated cancers
Supplementary Figure 1 from Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Authors: Pearson Alex , Proszek Paula , Pascual Javier , Fribbens Charlotte , Shamsher Monee K. , Kingston Belinda , O'Leary Ben , Herrera-Abreu Maria T. , Cutts Rosalind J. , Garcia-Murillas Isaac , Bye Hannah , Walker Brian A. , Gonzalez De Castro David , Yuan Lina , Jamal Sabri , Hubank Mike , Lopez-Knowles Elena , Schuster Eugene F. , Dowsett Mitch , Osin Peter , Nerurkar Ashutosh , Parton Marina , Okines Alicia F.C. , Johnston Stephen R.D. , Ring Alistair , Turner Nicholas C.
Published: April 2023

Genetic profile of advanced breast cancer subtypes
Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Cao Qi , Song Zhengshuai , Ruan Hailong , Wang Cheng , Yang Xiong , Bao Lin , Wang Keshan , Cheng Gong , Xu TianBo , Xiao Wen , Xiong Zhiyong , Liu Di , Yang Ming , Zhou Diwei , Yang Hongmei , Chen Ke , Zhang Xiaoping
Published: April 2023

Primers used in quantitative polymerase chain reaction for analysis of genomic amplification
Supplementary Figure S6 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Cao Qi , Song Zhengshuai , Ruan Hailong , Wang Cheng , Yang Xiong , Bao Lin , Wang Keshan , Cheng Gong , Xu TianBo , Xiao Wen , Xiong Zhiyong , Liu Di , Yang Ming , Zhou Diwei , Yang Hongmei , Chen Ke , Zhang Xiaoping
Published: April 2023

A and B, PC3 (A) and DU45 (B) cells with transiently knockdown of KIF4A. Cells were analyzed for cell proliferation by the CCK8 assay. C and D, PC3 (C) and DU45 (D) cells with transiently knockdown of KIF4A were treated with 20 μM enzalutamide. Cell proliferation was determined by the CCK8 assay. E, PC3 cells with stable AR expression were transfected with shRNA targeing KIF4A. Then cells were treated with 20 μM enzalutamide. Cell proliferation was determined by the CCK8 assay. F, C4-2-ENZ-R cells were transiently transfected with Flag-KIF4A and then treated with 20 μM enzalutamide. Cell proliferation was determined by the CCK8 assay. *p < 0.05; **p < 0.01, ***p < 0.001.
Supplemental Figure from Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer
Authors: Jeong Youngtae , Hellyer Jessica A. , Stehr Henning , Hoang Ngoc T. , Niu Xiaomin , Das Millie , Padda Sukhmani K. , Ramchandran Kavitha , Neal Joel W. , Wakelee Heather , Diehn Maximilian
Published: April 2023

Supplemental Figure 1
Supplementary Data from Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Authors: Nassar Amin H. , Umeton Renato , Kim Jaegil , Lundgren Kevin , Harshman Lauren , Van Allen Eliezer M. , Preston Mark , Dong Fei , Bellmunt Joaquim , Mouw Kent W. , Choueiri Toni K. , Sonpavde Guru , Kwiatkowski David J.
Published: April 2023

Survival of CREBBP-altered HG-NMIBC. A. Kaplan-Meier curve for recurrence-free survival in patients with CREBBP-altered compared to wild-type HG-NMIBC tumors. WT= wild type. B. Comparison of time to recurrence in those who recurred according to CREBBP mutation status.
Supplementary Figure S5 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Authors: Fernández-Nogueira Patricia , Mancino Mario , Fuster Gemma , López-Plana Anna , Jauregui Patricia , Almendro Vanesa , Enreig Estel , Menéndez Silvia , Rojo Federico , Noguera-Castells Aleix , Bill Anke , Gaither L. Alex , Serrano Laia , Recalde-Percaz Leire , Moragas Núria , Alonso Raul , Ametller Elisabet , Rovira Ana , Lluch Ana , Albanell Joan , Gascon Pere , Bragado Paloma
Published: April 2023

FGFR2 ligands and resistant cell lines conditioned media effect in breast cancer and fibroblast cell lines
eTable1 from Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Authors: Sjöström Martin , Chang S. Laura , Fishbane Nick , Davicioni Elai , Hartman Linda , Holmberg Erik , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Malmström Per , Fernö Mårten , Karlsson Per
Published: April 2023

genefu signatures
Supplementary Figure S2 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Authors: Fernández-Nogueira Patricia , Mancino Mario , Fuster Gemma , López-Plana Anna , Jauregui Patricia , Almendro Vanesa , Enreig Estel , Menéndez Silvia , Rojo Federico , Noguera-Castells Aleix , Bill Anke , Gaither L. Alex , Serrano Laia , Recalde-Percaz Leire , Moragas Núria , Alonso Raul , Ametller Elisabet , Rovira Ana , Lluch Ana , Albanell Joan , Gascon Pere , Bragado Paloma
Published: April 2023

Fibroblast effect on HER2 activation and HER2-targeted therapies sensitivity
Supplementary Methods from Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival
Authors: Tang Wei , Putluri Vasanta , Ambati Chandrashekar R. , Dorsey Tiffany H. , Putluri Nagireddy , Ambs Stefan
Published: April 2023

Methods
Supplemental Table 2 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Authors: Rotow Julia K. , Gui Philippe , Wu Wei , Raymond Victoria M. , Lanman Richard B. , Kaye Frederic J. , Peled Nir , Fece de la Cruz Ferran , Nadres Brandon , Corcoran Ryan B. , Yeh Iwei , Bastian Boris C. , Starostik Petr , Newsom Kimberly , Olivas Victor R. , Wolff Alexander M. , Fraser James S. , Collisson Eric A. , McCoach Caroline E. , Camidge D. Ross , Pacheco Jose , Bazhenova Lyudmila , Li Tianhong , Bivona Trever G. , Blakely Collin M.
Published: April 2023

Genes included in NGS Panels
Supplementary Table 2 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Authors: Wasserman Isaac , Lee Lik Hang , Ogino Shuji , Marco Michael R. , Wu Chao , Chen Xi , Datta Jashodeep , Sadot Eran , Szeglin Bryan , Guillem Jose G. , Paty Philip B. , Weiser Martin R. , Nash Garrett M. , Saltz Leonard , Barlas Afsar , Manova-Todorova Katia , Uppada Srijaya Prakash Babu , Elghouayel Arthur E. , Ntiamoah Peter , Glickman Jonathan N. , Hamada Tsuyoshi , Kosumi Keisuke , Inamura Kentaro , Chan Andrew T. , Nishihara Reiko , Cercek Andrea , Ganesh Karuna , Kemeny Nancy E. , Dhawan Punita , Yaeger Rona , Sawyers Charles L. , Garcia-Aguilar Julio , Giannakis Marios , Shia Jinru , Smith J. Joshua
Published: April 2023

Clinical, pathological, and molecular characteristics of colorectal cancer cases according to SMAD4 expression status in validation cohort
Supplementary Table 1 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Authors: Wasserman Isaac , Lee Lik Hang , Ogino Shuji , Marco Michael R. , Wu Chao , Chen Xi , Datta Jashodeep , Sadot Eran , Szeglin Bryan , Guillem Jose G. , Paty Philip B. , Weiser Martin R. , Nash Garrett M. , Saltz Leonard , Barlas Afsar , Manova-Todorova Katia , Uppada Srijaya Prakash Babu , Elghouayel Arthur E. , Ntiamoah Peter , Glickman Jonathan N. , Hamada Tsuyoshi , Kosumi Keisuke , Inamura Kentaro , Chan Andrew T. , Nishihara Reiko , Cercek Andrea , Ganesh Karuna , Kemeny Nancy E. , Dhawan Punita , Yaeger Rona , Sawyers Charles L. , Garcia-Aguilar Julio , Giannakis Marios , Shia Jinru , Smith J. Joshua
Published: April 2023

Ratio and concentrations of FOLFOX in discovery cohort.
Supplementary Data from Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Authors: Malekzadeh Parisa , Yossef Rami , Cafri Gal , Paria Biman C. , Lowery Frank J. , Jafferji Mohammad , Good Meghan L. , Sachs Abraham , Copeland Amy R. , Kim Sanghyun P. , Kivitz Scott , Parkhurst Maria R. , Robbins Paul F. , Ray Satyajit , Xi Liqiang , Raffeld Mark , Yu Zhiya , Restifo Nicholas P. , Somerville Robert P.T. , Rosenberg Steven A. , Deniger Drew C.
Published: April 2023

Table 1: Antibodies used in the study. Table 2: Normalized initial screening data from PBL with a T cell response to mutated TP53. Table 3: TCRB tracking of p53 neoantigen-reactive cells before and after IVS, co-culture, 41BB/OX40 sorting and REP.
Supplementary Figure 2 from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Figure 2 and Legend
Supplementary Data from A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Authors: Gatti-Mays Margaret E. , Strauss Julius , Donahue Renee N. , Palena Claudia , Del Rivero Jaydira , Redman Jason M. , Madan Ravi A. , Marté Jennifer L. , Cordes Lisa M. , Lamping Elizabeth , Orpia Alanvin , Burmeister Andrea , Wagner Eva , Pico Navarro Cesar , Heery Christopher R. , Schlom Jeffrey , Gulley James L.
Published: April 2023

Supplementary Table S1A: Phenotypic analysis of surface markers on human DCs transfected with MVA-BN-CV301 and FPV-CV301 vectors Supplementary Table S1B: Activation of CEA- and MUC1-specific T-cells by MVA-BN-CV301 and FPV-CV301 Supplementary Table S2: Number of patients reporting adverse events possibly, probably or definitely attributed to CV301 (n=202 events in total) Supplementary Table S3: Development of CEA- and MUC1-specific T-cells by BN-CV301 Supplementary Figure S1: KRAS specific responses assessed in 3 patients preâ€' and postâ€'BN- CV301 vaccine
Supplementary Table S2 from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Authors: Hurvitz Sara A. , Martin Miguel , Press Michael F. , Chan David , Fernandez-Abad María , Petru Edgar , Rostorfer Regan , Guarneri Valentina , Huang Chiun-Sheng , Barriga Susana , Wijayawardana Sameera , Brahmachary Manisha , Ebert Philip J. , Hossain Anwar , Liu Jiangang , Abel Adam , Aggarwal Amit , Jansen Valerie M. , Slamon Dennis J.
Published: April 2023

Median Ki67 expression by tumor grade.
Supplementary Table S1 from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Authors: Hurvitz Sara A. , Martin Miguel , Press Michael F. , Chan David , Fernandez-Abad María , Petru Edgar , Rostorfer Regan , Guarneri Valentina , Huang Chiun-Sheng , Barriga Susana , Wijayawardana Sameera , Brahmachary Manisha , Ebert Philip J. , Hossain Anwar , Liu Jiangang , Abel Adam , Aggarwal Amit , Jansen Valerie M. , Slamon Dennis J.
Published: April 2023

Molecular subtypes at baseline.
Supplementary Figure S5 from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Authors: Hurvitz Sara A. , Martin Miguel , Press Michael F. , Chan David , Fernandez-Abad María , Petru Edgar , Rostorfer Regan , Guarneri Valentina , Huang Chiun-Sheng , Barriga Susana , Wijayawardana Sameera , Brahmachary Manisha , Ebert Philip J. , Hossain Anwar , Liu Jiangang , Abel Adam , Aggarwal Amit , Jansen Valerie M. , Slamon Dennis J.
Published: April 2023

A. Analysis of the RNAseq samples. B. Top downregulated gene set enrichment analysis (GSEA) gene sets across treatment arms. C. Top upregulated GSEA gene sets in the combination treatment arm.
Supplementary Figure S1. from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Authors: Hurvitz Sara A. , Martin Miguel , Press Michael F. , Chan David , Fernandez-Abad María , Petru Edgar , Rostorfer Regan , Guarneri Valentina , Huang Chiun-Sheng , Barriga Susana , Wijayawardana Sameera , Brahmachary Manisha , Ebert Philip J. , Hossain Anwar , Liu Jiangang , Abel Adam , Aggarwal Amit , Jansen Valerie M. , Slamon Dennis J.
Published: April 2023

A. neoMONARCH consort diagram. B-D. Clinical and radiologic, and pathologic responses in neoMONARCH.
Supplementary Data from A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition
Authors: Shee Kevin , Wells Jason D. , Ung Matthew , Hampsch Riley A. , Traphagen Nicole A. , Yang Wei , Liu Stephanie C. , Zeldenrust Megan A. , Wang Liewei , Kalari Krishna R. , Yu Jia , Boughey Judy C. , Demidenko Eugene , Kettenbach Arminja N. , Cheng Chao , Goetz Matthew P. , Miller Todd W.
Published: April 2023

Suppl Data and Methods Fig. S1. Flowchart of experimental approach. Fig. S2. Unsupervised hierarchical clustering of breast or ovarian cancer cell lines confirms known subtypes. Fig. S3. Validation of BR/OV-1 and -2 clusters of BRCA and OVCA cell lines. Fig. S4. BR/OV-1 and -2 subgroups of cell lines exhibit differential Hsp90i sensitivity in GDSC database v7. Fig. S5. Support vector machine (SVM) classifier validates robustness of BR/OV-1/2 gene expression classifier to predict BR/OV-1/2 status in an independent dataset. Fig. S6. Validation of BR/OV-1 and -2 subgroups at the (phospho)protein level. Fig. S7. BR/OV-1 and -2 subgroups are distinguishable by proteomics. Fig. S8. Individual dose-response curves for BR/OV-1 and -2 TNBC and OVCA cell lines treated with CCT018159. Fig. S9. Differential sensitivity of BR/OV-1 vs. -2 cell lines to Hsp90 inhibition is lineage-independent. Fig. S10. Individual dose-response curves for TNBC and OVCA cell lines subtyped as BR/OV-1 or -2. Fig. S11. Effects of Hsp90 inhibition on (phospho)protein expression in BR/OV-1 TNBC and OVCA cells. Fig. S12. Effects of Hsp90 inhibition on (phospho)protein expression in BR/OV-2 TNBC and OVCA cells. Fig. S13. Hsp90 inhibition induces apoptosis in BR/OV-2 but not BR/OV-1 TNBC and OVCA cells. Fig. S14. Individual growth curves of OVCA xenografts. Fig. S15. Representative Ki67 IHC and TUNEL images of OVCA xenografts. Fig. S16. Individual growth curves of breast cancer PDX tumors. Fig. S17. Body weight monitoring of mice bearing breast cancer PDX tumors. Fig. S18. Representative Ki67 IHC and TUNEL images of breast cancer PDX tumors. Fig. S19. Assessing homologous recombination deficiency (HRD)-related genetic alterations in tumor models.
Supplementary Data Legends from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

Supplementary figure and table legends
Figure S2 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

CBFA2T3 expression in lymphomas
Figure S1 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

CSF1R expression in lymphomas
Appendix Table 1. from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Authors: Pakarainen Tomi , Nevalainen Jaakko , Talala Kirsi , Taari Kimmo , Raitanen Jani , Kujala Paula , Stenman Ulf-Håkan , Tammela Teuvo L.J. , Auvinen Anssi
Published: April 2023

Results of the case-control study
Figure S2 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Authors: House Imran G. , Savas Peter , Lai Junyun , Chen Amanda X.Y. , Oliver Amanda J. , Teo Zhi L. , Todd Kirsten L. , Henderson Melissa A. , Giuffrida Lauren , Petley Emma V. , Sek Kevin , Mardiana Sherly , Gide Tuba N. , Quek Camelia , Scolyer Richard A. , Long Georgina V. , Wilmott James S. , Loi Sherene , Darcy Phillip K. , Beavis Paul A.
Published: April 2023

Figure S2 shows the expression of chemokines following single agent anti-PD-1 therapy in patients and their association with patient prognosis and immune cell infiltrate.
Figure S1 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Authors: House Imran G. , Savas Peter , Lai Junyun , Chen Amanda X.Y. , Oliver Amanda J. , Teo Zhi L. , Todd Kirsten L. , Henderson Melissa A. , Giuffrida Lauren , Petley Emma V. , Sek Kevin , Mardiana Sherly , Gide Tuba N. , Quek Camelia , Scolyer Richard A. , Long Georgina V. , Wilmott James S. , Loi Sherene , Darcy Phillip K. , Beavis Paul A.
Published: April 2023

Figure S1 shows the response of AT-3 ova tumors to single agent anti-PD-1 or anti-CTLA-4 and the upregulation of chemokine receptors or chemokines following dual or single agent therapy.
Table S4 from Genetic Ancestry–dependent Differences in Breast Cancer–induced Field Defects in the Tumor-adjacent Normal Breast
Authors: Nakshatri Harikrishna , Kumar Brijesh , Burney Heather N. , Cox Mary L. , Jacobsen Max , Sandusky George E. , D'Souza-Schorey Crislyn , Storniolo Anna Maria V.
Published: April 2023

Differences in Komen normal women by BMI
Table S1 from Genetic Ancestry–dependent Differences in Breast Cancer–induced Field Defects in the Tumor-adjacent Normal Breast
Authors: Nakshatri Harikrishna , Kumar Brijesh , Burney Heather N. , Cox Mary L. , Jacobsen Max , Sandusky George E. , D'Souza-Schorey Crislyn , Storniolo Anna Maria V.
Published: April 2023

Descriptive Statistics for the Komen-Normal breast tissue
Supplementary Tables from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Authors: Gerber David E. , Infante Jeffrey R. , Gordon Michael S. , Goldberg Sarah B. , Martín Miguel , Felip Enriqueta , Martinez Garcia Maria , Schiller Joan H. , Spigel David R. , Cordova Julie , Westcott Valerie , Wang Yulei , Shames David S. , Choi YounJeong , Kahn Robert , Dere Randall C. , Samineni Divya , Xu Jian , Lin Kedan , Wood Katie , Royer-Joo Stephanie , Lemahieu Vanessa , Schuth Eva , Vaze Anjali , Maslyar Daniel , Humke Eric W. , Burris Howard A.
Published: April 2023

Supplementary Table S1. Adverse events regardless of relationship to study drug occurring in 10 or more patients Supplementary Table S2. Adverse events grades 3-5 regardless of relationship to study drug occurring in 2 or more patients Supplementary Table S3. Pulmonary adverse events by frequency of occurrence in all patients regardless of relationship to study drug Supplementary Table S4. Pulmonary adverse events of NCI-CTCAE grade 3 or higher by frequency of occurrence in all patients regardless of relationship to study drug Supplementary Table S5. Mean (standard deviation) of the pharmacokinetic parameters for antibody-conjugated MMAE in plasma Supplementary Table S6. Mean (standard deviation) of the pharmacokinetic parameters for total antibody in plasma Supplementary Table S7. Mean (standard deviation) of the pharmacokinetic parameters for unconjugated MMAE in plasma Supplementary Table S8. Response outcomes and duration
Supplementary Figure 2 from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Authors: Gerber David E. , Infante Jeffrey R. , Gordon Michael S. , Goldberg Sarah B. , Martín Miguel , Felip Enriqueta , Martinez Garcia Maria , Schiller Joan H. , Spigel David R. , Cordova Julie , Westcott Valerie , Wang Yulei , Shames David S. , Choi YounJeong , Kahn Robert , Dere Randall C. , Samineni Divya , Xu Jian , Lin Kedan , Wood Katie , Royer-Joo Stephanie , Lemahieu Vanessa , Schuth Eva , Vaze Anjali , Maslyar Daniel , Humke Eric W. , Burris Howard A.
Published: April 2023

Supplementary Figure S2. Representative NaPi2b ICH images for PROC and NSCLC patients.
Table S1, Table S2 from A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Authors: Goyal Lipika , Zheng Hui , Abrams Thomas A. , Miksad Rebecca , Bullock Andrea J. , Allen Jill N. , Yurgelun Matthew B. , Clark Jeffrey W. , Kambadakone Avinash , Muzikansky Alona , Knowles Michelle , Galway Aralee , Afflitto Anthony J. , Dinicola Caroline F. , Regan Eileen , Hato Tai , Mamessier Emilie , Shigeta Kohei , Jain Rakesh K. , Duda Dan G. , Zhu Andrew X.
Published: April 2023

Table S1 displays second line therapies that patients pursued. Table S2 displays baseline and change (%) in plasma and cellular biomarkers.
Table S3 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Gene ontology features in metformin vs. fibrotic human ovaries
Table S1 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Gene ontology features in fibrotic vs. non-fibrotic human ovaries
Supplementary Legend from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Supplementary Legend
Supplementary Data File S1 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Supplementary Data File S1
Table S3 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Authors: Buhl Juliane L. , Selt Florian , Hielscher Thomas , Guiho Romain , Ecker Jonas , Sahm Felix , Ridinger Johannes , Riehl Dennis , Usta Diren , Ismer Britta , Sommerkamp Alexander C. , Martinez-Barbera J.P. , Wefers Annika K. , Remke Marc , Picard Daniel , Pusch Stefan , Gronych Jan , Oehme Ina , van Tilburg Cornelis M. , Kool Marcel , Kuhn Daniela , Capper David , von Deimling Andreas , Schuhmann Martin U. , Herold-Mende Christel , Korshunov Andrey , Brummer Tilman , Pfister Stefan M. , Jones David T.W. , Witt Olaf , Milde Till
Published: April 2023

GEP results of SASP in DKFZ-BT66 in OIS vs. proliferation
Supplemental Table Legend from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Authors: Buhl Juliane L. , Selt Florian , Hielscher Thomas , Guiho Romain , Ecker Jonas , Sahm Felix , Ridinger Johannes , Riehl Dennis , Usta Diren , Ismer Britta , Sommerkamp Alexander C. , Martinez-Barbera J.P. , Wefers Annika K. , Remke Marc , Picard Daniel , Pusch Stefan , Gronych Jan , Oehme Ina , van Tilburg Cornelis M. , Kool Marcel , Kuhn Daniela , Capper David , von Deimling Andreas , Schuhmann Martin U. , Herold-Mende Christel , Korshunov Andrey , Brummer Tilman , Pfister Stefan M. , Jones David T.W. , Witt Olaf , Milde Till
Published: April 2023

Supplemental Table Legend
Supplementary Legend from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

Supplementary Legend
Figure S7 from Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Authors: Chen Xiaoji , Chang Ching-Wei , Spoerke Jill M. , Yoh Kathryn E. , Kapoor Vidushi , Baudo Charles , Aimi Junko , Yu Mamie , Liang-Chu May M.Y. , Suttmann Rebecca , Huw Ling-Yuh , Gendreau Steven , Cummings Craig , Lackner Mark R.
Published: April 2023

cfDNA tumor fraction dynamics.
Figure S5 from Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Authors: Chen Xiaoji , Chang Ching-Wei , Spoerke Jill M. , Yoh Kathryn E. , Kapoor Vidushi , Baudo Charles , Aimi Junko , Yu Mamie , Liang-Chu May M.Y. , Suttmann Rebecca , Huw Ling-Yuh , Gendreau Steven , Cummings Craig , Lackner Mark R.
Published: April 2023

REMARK diagram, CNV landscape and frequency of non-squamous, and tumor fraction distribution
Cox regression of individual genes related to T cell evasion from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

Univariate cox-regression analysis of genes related to T cell evasion per molecular subtype (with MFS)
Supplementary Data Table S1, 3-4 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Authors: Shi Ruoshi , Radulovich Nikolina , Ng Christine , Liu Ni , Notsuda Hirotsugu , Cabanero Michael , Martins-Filho Sebastiao N. , Raghavan Vibha , Li Quan , Mer Arvind Singh , Rosen Joshua C. , Li Ming , Wang Yu-Hui , Tamblyn Laura , Pham Nhu-An , Haibe-Kains Benjamin , Liu Geoffrey , Moghal Nadeem , Tsao Ming-Sound
Published: April 2023

Supplementary Data Table S1, 3-4
Supplementary Table 2 from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia
Authors: Jin Qi , Martinez Carlos A. , Arcipowski Kelly M. , Zhu Yixing , Gutierrez-Diaz Blanca T. , Wang Kenneth K. , Johnson Megan R. , Volk Andrew G. , Wang Feng , Wu Jian , Grove Charles , Wang Hui , Sokirniy Ivan , Thomas Paul M. , Goo Young Ah , Abshiru Nebiyu A. , Hijiya Nobuko , Peirs Sofie , Vandamme Niels , Berx Geert , Goosens Steven , Marshall Stacy A. , Rendleman Emily J. , Takahashi Yoh-hei , Wang Lu , Rawat Radhika , Bartom Elizabeth T. , Collings Clayton K. , Van Vlierberghe Pieter , Strikoudis Alexandros , Kelly Stephen , Ueberheide Beatrix , Mantis Christine , Kandela Irawati , Bourquin Jean-Pierre , Bornhauser Beat , Serafin Valentina , Bresolin Silvia , Paganin Maddalena , Accordi Benedetta , Basso Giuseppe , Kelleher Neil L. , Weinstock Joseph , Kumar Suresh , Crispino John D. , Shilatifard Ali , Ntziachristos Panagiotis
Published: April 2023

Supplementary Table 2
Supplementary Data Legends from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Authors: Courtney Kevin D. , Ma Yuanqing , Diaz de Leon Alberto , Christie Alana , Xie Zhiqun , Woolford Layton , Singla Nirmish , Joyce Allison , Hill Haley , Madhuranthakam Ananth J. , Yuan Qing , Xi Yin , Zhang Yue , Chang Jenny , Fatunde Oluwatomilade , Arriaga Yull , Frankel Arthur E. , Kalva Sanjeeva , Zhang Song , McKenzie Tiffani , Reig Torras Oscar , Figlin Robert A. , Rini Brian I. , McKay Renée M. , Kapur Payal , Wang Tao , Pedrosa Ivan , Brugarolas James
Published: April 2023

Supplementary Data Legends
Supplementary Materials from Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy
Authors: Gounder Mrinal M. , Zhu Guo , Roshal Lev , Lis Eric , Daigle Scott R. , Blakemore Steven J. , Michaud Neil R. , Hameed Meera , Hollmann Travis J.
Published: April 2023

Supplementary Materials and Methods Supplementary Table 1
Table S1 from Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Authors: Hassan Raffit , Alley Evan , Kindler Hedy , Antonia Scott , Jahan Thierry , Honarmand Somayeh , Nair Nitya , Whiting Chan C. , Enstrom Amanda , Lemmens Ed , Tsujikawa Takahiro , Kumar Sushil , Choe Gina , Thomas Anish , McDougall Katherine , Murphy Aimee L. , Jaffee Elizabeth , Coussens Lisa M. , Brockstedt Dirk G.
Published: April 2023

Biomarkers utilized for defining immune cell lineages in IHC analysis
Supplementary Data from MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Authors: Chalishazar Milind D. , Wait Sarah J. , Huang Fang , Ireland Abbie S. , Mukhopadhyay Anandaroop , Lee Younjee , Schuman Sophia S. , Guthrie Matthew R. , Berrett Kristofer C. , Vahrenkamp Jeffery M. , Hu Zeping , Kudla Marek , Modzelewska Katarzyna , Wang Guoying , Ingolia Nicholas T. , Gertz Jason , Lum David H. , Cosulich Sabina C. , Bomalaski John S. , DeBerardinis Ralph J. , Oliver Trudy G.
Published: April 2023

Supplemental Figures 1-6 and Supplemental Methods
Figure S4 from Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Authors: Hassan Raffit , Alley Evan , Kindler Hedy , Antonia Scott , Jahan Thierry , Honarmand Somayeh , Nair Nitya , Whiting Chan C. , Enstrom Amanda , Lemmens Ed , Tsujikawa Takahiro , Kumar Sushil , Choe Gina , Thomas Anish , McDougall Katherine , Murphy Aimee L. , Jaffee Elizabeth , Coussens Lisa M. , Brockstedt Dirk G.
Published: April 2023

Kinetics of osteopontin and CA-125.
Supplementary Table 5 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Teixeira Luis , Medioni Jacques , Garibal Julie , Adotevi Olivier , Doucet Ludovic , Durey Marie-Agnès Dragon , Ghrieb Zineb , Kiladjian Jean-Jacques , Brizard Mara , Laheurte Caroline , Wehbe Maria , Pliquet Elodie , Escande Marie , Defrance Rémy , Culine Stephane , Oudard Stephane , Wain-Hobson Simon , Doppler Valérie , Huet Thierry , Langlade-Demoyen Pierre
Published: April 2023

Clinical features of patients with OS <1 year vs. patients with OS >1 year
Supplementary Table 4 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Teixeira Luis , Medioni Jacques , Garibal Julie , Adotevi Olivier , Doucet Ludovic , Durey Marie-Agnès Dragon , Ghrieb Zineb , Kiladjian Jean-Jacques , Brizard Mara , Laheurte Caroline , Wehbe Maria , Pliquet Elodie , Escande Marie , Defrance Rémy , Culine Stephane , Oudard Stephane , Wain-Hobson Simon , Doppler Valérie , Huet Thierry , Langlade-Demoyen Pierre
Published: April 2023

Best Overall Response
Figure S2 from Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Authors: Hassan Raffit , Alley Evan , Kindler Hedy , Antonia Scott , Jahan Thierry , Honarmand Somayeh , Nair Nitya , Whiting Chan C. , Enstrom Amanda , Lemmens Ed , Tsujikawa Takahiro , Kumar Sushil , Choe Gina , Thomas Anish , McDougall Katherine , Murphy Aimee L. , Jaffee Elizabeth , Coussens Lisa M. , Brockstedt Dirk G.
Published: April 2023

Intratumoral leukocyte composition of mesothelioma representing pre- and post-therapy immunotherapy, evaluated by multiplex IHC.
Figure S1 from Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Authors: Hassan Raffit , Alley Evan , Kindler Hedy , Antonia Scott , Jahan Thierry , Honarmand Somayeh , Nair Nitya , Whiting Chan C. , Enstrom Amanda , Lemmens Ed , Tsujikawa Takahiro , Kumar Sushil , Choe Gina , Thomas Anish , McDougall Katherine , Murphy Aimee L. , Jaffee Elizabeth , Coussens Lisa M. , Brockstedt Dirk G.
Published: April 2023

Study design
Supplementary Figure 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Teixeira Luis , Medioni Jacques , Garibal Julie , Adotevi Olivier , Doucet Ludovic , Durey Marie-Agnès Dragon , Ghrieb Zineb , Kiladjian Jean-Jacques , Brizard Mara , Laheurte Caroline , Wehbe Maria , Pliquet Elodie , Escande Marie , Defrance Rémy , Culine Stephane , Oudard Stephane , Wain-Hobson Simon , Doppler Valérie , Huet Thierry , Langlade-Demoyen Pierre
Published: April 2023

Kaplan-Meier representation of Overall Survival and Progression Free Survival
Supplementary Data from Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
Authors: Fennell Dean A. , Danson Sarah , Woll Penella J. , Forster Martin , Talbot Denis , Child Jennifer , Farrelly Laura , Sharkey Annabel , Busacca Sara , Ngai Yenting , Hackshaw Allan , Wheeler Graham M.
Published: April 2023

Supplementary Tables 1-5 and Supplementary Figures 1-7. Includes results on treatment compliance, dose-limiting toxicities, genomic variable analyses and Kaplan-Meier plots for time-to-event outcomes.
Figure S4 from Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo
Authors: Naz Sarwat , Sowers Anastasia , Choudhuri Rajani , Wissler Maria , Gamson Janet , Mathias Askale , Cook John A. , Mitchell James B.
Published: April 2023

Figure S4. (A) Pilot H460 xenograft study combining Abemaciclib and fractionated radiation (2 Gy x 3). Once tumors reached size of 200 mm3, the tumor bearing legs were exposed to local fractionated radiation (2 Gy) on Monday, Wednesday and Friday followed by two daily gavages of Abemaciclib (100 mg/kg) on Monday and Tuesday. Two doses of Abemaciclib per day was not well tolerated and subsequently mice where given single Abemaciclib doses on Wed-Fri. The combination of XRT and Abemaciclib resulted in modest enhancement of tumor radiosensitivity. (B) Western blot analysis of H460 xenograft showing CDK4/6 target inhibition. Expression of RB/E2F target cyclin A is shown. Changes in p-ERK1/2 and p-S6 is also shown for xenografts receiving Abemaciclib treatment for week 1 and week 2 post fractionated radiation. (C) H460 xenograft showing enhanced tumor regrowth delay by daily administration of 100mg/kg body weight of Abemaciclib through oral gavage for 5 days immediately after 2 Gyx3 IR dose administered every alternate day indicated as week 1. The drug dosing was continued for another 5 days indicated as week 2. The significance for tumor regrowth delay was measured when tumor size reached 800mm3. The statistical significance is derived from 8 animals per group.
Supplementary Tables 1-2, Supplementary Figures 1-4 from Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Authors: Oweida Ayman , Hararah Mohammad K. , Phan Andy , Binder David , Bhatia Shilpa , Lennon Shelby , Bukkapatnam Sanjana , Van Court Benjamin , Uyanga Nomin , Darragh Laurel , Kim Hyun Min , Raben David , Tan Aik Choon , Heasley Lynn , Clambey Eric , Nemenoff Raphael , Karam Sana D.
Published: April 2023

Supplementary Table 1 â€" Effect of varying RT regimen and dose on survival when combined with anti PD-L1 in orthotopic Balb/c mice harboring LY2 tumors; Supplementary Table 2A â€" Effect of varying combinations of RT and dual immune checkpoint on survival in LY2 mice; Supplementary Figure 1 â€" Cibersort analysis of RNAseq data obtained from orthotopic LY2, MOC1 and MOC2 tumors. Supplementary Figure 2 â€" Tumor growth curves for (A) LY2 and (B) MOC2 tumors treated with anti-PD-L1 and anti-TIM-3 alone and in combination with RT; Supplementary Figure 3 â€" Analysis of relative abundance of mRNA transcript levels of genes involved in Treg differentiation and homing and effector T cell function from LY2 tumors harvested 1-week and 3-weeks after initiation of RT and anti-PD-L1 treatment; Supplementary Figure 4 â€" Analysis of patient samples with the Vectra immuno-fluorescence platform. Two patients with similar disease course but different outcomes were selected for analysis of immune cell profile (CD3, CD8, CD4, FoxP3, DAPI).
Figure S2 from Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo
Authors: Naz Sarwat , Sowers Anastasia , Choudhuri Rajani , Wissler Maria , Gamson Janet , Mathias Askale , Cook John A. , Mitchell James B.
Published: April 2023

Figure S2. (A) Immunoblot analysis showing expression of DNA damage repair proteins in H1299 cells post-IR and Abemaciclib treatment. (B) Immunoblot analysis showing target inhibition in H1975 cells post-IR and Abemaciclib treatment (C) Immunofluorescence expression of p-RB (Ser811/780, shown in green) for H460 cells treated with Abemaciclib for 4 hour and 24 hour. Nucleus was stained with DAPI, 4',6-diamidino-2-phenylindole (show in blue). (D and E) Flow cytometry analysis showing percentage (%) of cells positive for p-HH3 (Ser10, 1:100 dilution) expression (D) and AnnexinV (1:100) +PI (propidium iodide, 5ug/ml) positive (E) post Abemaciclib+IR treatment for 24 hours.
Supplementary Figure 6 from Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors: Seo Yongwoo David , Jiang Xiuyun , Sullivan Kevin M. , Jalikis Florencia G. , Smythe Kimberly S. , Abbasi Arezou , Vignali Marissa , Park James O. , Daniel Sara K. , Pollack Seth M. , Kim Teresa S. , Yeung Raymond , Crispe Ian Nicholas , Pierce Robert H. , Robins Harlan , Pillarisetty Venu G.
Published: April 2023

Image cytometry methods overview
Supplementary Table Legend from Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
Authors: Hu-Lieskovan Siwen , Lisberg Aaron , Zaretsky Jesse M. , Grogan Tristan R. , Rizvi Hira , Wells Daniel K. , Carroll James , Cummings Amy , Madrigal John , Jones Benjamin , Gukasyan Jacklin , Shintaku I. Peter , Slamon Dennis , Dubinett Steven , Goldman Jonathan W. , Elashoff David , Hellmann Matthew D. , Ribas Antoni , Garon Edward B.
Published: April 2023

Supplementary Table Legend
Supplementary Figure 2 from Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors: Seo Yongwoo David , Jiang Xiuyun , Sullivan Kevin M. , Jalikis Florencia G. , Smythe Kimberly S. , Abbasi Arezou , Vignali Marissa , Park James O. , Daniel Sara K. , Pollack Seth M. , Kim Teresa S. , Yeung Raymond , Crispe Ian Nicholas , Pierce Robert H. , Robins Harlan , Pillarisetty Venu G.
Published: April 2023

TCR overlap analysis
Supplementary Data from Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia
Authors: Wang Wen-Tao , Han Cai , Sun Yu-Meng , Chen Zhen-Hua , Fang Ke , Huang Wei , Sun Lin-Yu , Zeng Zhan-Cheng , Luo Xue-Qun , Chen Yue-Qin
Published: April 2023

Supplementary tables including Table S1 Patient demographics and clinicopathologic features,Table S2 The primers used in this work,Table S3 SiRNA/shRNA, and Table S4 The antibodies and drugs used in the study.
Table S2 from Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics
Authors: Yim John H. , Choi Audrey H. , Li Arthur X. , Qin Hanjun , Chang Sue , Tong Sun-Wing T. , Chu Peiguo , Kim Byung-Wook , Schmolze Daniel , Lew Ryan , Ibrahim Yasmine , Poroyko Valeriy A. , Salvatierra Sylvana , Baker Alysha , Wang Jinhui , Wu Xiwei , Pfeifer Gerd P. , Fong Yuman , Hahn Maria A.
Published: April 2023

Genomic locations associated with benign and malignant epigenetic signatures for thyroid nodule diagnostics and an association of these locations with H3K27Ac peaks and H3K27Ac associated areas (peaks including enhancer shores).